Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Operating Expenses (2020 - 2025)

Gain Therapeutics has reported Operating Expenses over the past 6 years, most recently at $4.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $4.5 million for Q4 2025, up 34.07% from a year ago — trailing twelve months through Dec 2025 was $18.7 million (down 8.06% YoY), and the annual figure for FY2025 was $18.7 million, down 8.06%.
  • Operating Expenses for Q4 2025 was $4.5 million at Gain Therapeutics, down from $4.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for GANX hit a ceiling of $8.2 million in Q2 2024 and a floor of $2.5 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $4.5 million (2022), compared with a mean of $4.7 million.
  • Biggest five-year swings in Operating Expenses: soared 568.8% in 2021 and later crashed 37.8% in 2025.
  • Gain Therapeutics' Operating Expenses stood at $3.3 million in 2021, then skyrocketed by 40.26% to $4.6 million in 2022, then fell by 3.38% to $4.4 million in 2023, then fell by 24.42% to $3.3 million in 2024, then skyrocketed by 34.07% to $4.5 million in 2025.
  • The last three reported values for Operating Expenses were $4.5 million (Q4 2025), $4.8 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.